Archives
-
Zika Virus Phosphoproteome Maps Host Regulation
2026-10-07
A 2026 PLOS Pathogens study created a global mass-spectrometry map of host-driven post-translational modifications across eight Zika virus proteins. The work links envelope-protein phosphorylation with viral particle release and cytopathogenicity, while identifying host kinase interactions and Bosutinib-sensitive regulation as important directions for antiviral research.
-
CMC Lessons for Translating mRNA Lipid Nanoparticles
2026-10-06
Liu and colleagues present a CMC-centered framework for translating mRNA lipid nanoparticles, connecting lipid chemistry, manufacturing choices, critical quality attributes, analytical characterization, and scale-change comparability. The review’s main contribution is organizational and translational rather than a new formulation: it shows why delivery performance must be evaluated together with manufacturability, stability, impurity control, and regulatory evidence.
-
Cy3 TSA Fluorescence System Kit for Astrocyte Mapping
2026-10-05
The Cy3 TSA Fluorescence System Kit can provide a conceptual bridge between astrocyte transcriptomic atlases and spatial fluorescence microscopy detection. This article examines how tyramide amplification may support orthogonal validation while distinguishing molecular localization from quantitative expression.
-
PD0325901: MEK Inhibition in Cancer Research
2026-10-05
This source-grounded overview examines PD0325901 as a research tool for studying MEK–ERK signaling, reported effects on proliferation and tumor models, and the relevance—but not direct applicability—of recent single-molecule chromatin research. It distinguishes supplier-reported findings from published evidence and outlines key limitations without providing experimental procedures.
-
Multiple Myeloma Cell Lines: Mutation and Drug Response
2026-10-04
A 2019 Theranostics study used whole-exome sequencing across 30 human multiple myeloma cell lines to define recurrent mutations, altered pathways, and links between genotype and drug response. Its main contribution is a molecular reference framework for selecting cell-line models, while its findings remain associative and require validation in primary tumors and relevant microenvironmental systems.
-
APEX2 Supports TERT Expression in Human Stem Cells
2026-10-01
A bioRxiv preprint reports that APEX2, but not its paralog APEX1, is required for efficient TERT expression and telomerase activity in human embryonic stem cells and a melanoma cell line. RNA-seq and chromatin immunoprecipitation connect this effect to APEX2 association with repetitive MIR and Alu-rich DNA, suggesting that DNA repair at TERT-associated repeats may influence gene expression.
-
Gepotidacin–Gyrase Mechanism in S. aureus
2026-10-01
The reference study defines how gepotidacin inhibits Staphylococcus aureus gyrase through a cleavage pattern that differs fundamentally from that of fluoroquinolones. Biochemical assays and crystal structures show selective stabilization of single-stranded DNA breaks, providing a mechanistic framework for developing antibacterial agents that can retain activity against fluoroquinolone-resistant bacteria.
-
Perospirone (SM-9018 freebase) Assay Guide
2026-10-01
A scenario-driven guide to using Perospirone (SM-9018 freebase), SKU BA5009, in viability, proliferation, receptor-mechanism, and vascular electrophysiology workflows. It addresses solvent compatibility, assay interpretation, storage, and vendor-selection decisions using product specifications and peer-reviewed Kv-channel data.
-
AZD3463: ALK/IGF1R Inhibitor Workflow
2026-09-30
AZD3463 provides a practical way to interrogate ALK- and IGF1R-dependent signaling, apoptosis, autophagy, and chemotherapy response in neuroblastoma models. This workflow combines genotype-aware dosing, pathway-resolved readouts, and reproducibility principles adapted from a chemically defined stem-cell differentiation study.
-
BAPTA for Calcium Signaling and Apoptosis
2026-09-29
BAPTA provides a practical way to test whether free Ca2+ is a causal signal rather than a downstream marker in toxicology, apoptosis, and cell signaling studies. This guide translates a nanoplastic–cadmium intestinal-cell model into reproducible preparation, dosing, control, and troubleshooting workflows.
-
CXCR4 Theranostics in Lymphoma: Imaging to Therapy
2026-09-29
The 2026 review by Dhamecha and colleagues presents CXCR4 as a receptor-level bridge between lymphoma imaging, prognostic assessment, and targeted treatment. It organizes peptide radiotracers, small molecules, radioligand therapies, and antibodies into a theranostic framework while emphasizing physiological off-target uptake and CXCR7 compensation as major translational limitations.
-
Marein Reverses ABCG2-Mediated Drug Resistance
2026-09-28
A 2024 Biochemical Pharmacology study identifies marein, a flavonoid from Coreopsis tinctoria, as a competitive inhibitor of the ABCG2 drug-efflux transporter. By increasing intracellular levels of ABCG2 substrates—including mitoxantrone, topotecan, and olaparib—the study provides a mechanistic framework for restoring chemosensitivity in transporter-overexpressing cancer cells.
-
METTL16–SENP3–LTF and Ferroptosis Resistance in HCC
2026-09-28
Wang et al. identify a METTL16–SENP3–LTF pathway that lowers the labile iron pool and helps hepatocellular carcinoma cells resist ferroptosis. Their multi-model evidence connects m6A-dependent regulation of SENP3 to LTF stability and tumor progression, highlighting an iron-metabolism mechanism for further study rather than validating a particular iron chelator as a treatment.
-
ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors
2026-09-27
A preclinical study found that ATRX-deficient high-grade glioma cells were more sensitive to several receptor tyrosine kinase and PDGFR inhibitors than ATRX-proficient comparators. The results also point to a potential benefit from combining RTK inhibition with temozolomide, while underscoring the need to evaluate ATRX status in relevant clinical-trial analyses.
-
Cancer Drug Response Beyond Relative Viability
2026-09-26
Hannah R. Schwartz’s dissertation distinguishes relative viability, which combines effects on proliferation and cell death, from fractional viability, which focuses on cell killing. Its central finding—that drugs affect growth and death in different proportions and on different timelines—supports measuring these responses separately rather than treating one viability endpoint as a complete account of drug activity.